Amgen Inc. (AMGN)
Can Amgen Keep the Beat Streak Alive This Earnings Season?
Volume growth of AMGN's key drugs like Evenity, Repatha and Kyprolis is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Will These 5 Big Drug Stocks Surpass Q1 Earnings Forecasts?
Let's look at five pharma and drug companies, PFE, LLY, AMGN, BIIB and REGN, which are scheduled to release their first-quarter 2025 results later this week.
Amgen (AMGN) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Amgen (AMGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.
Amgen (AMGN) Earnings Expected to Grow: Should You Buy?
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Most-Watched Stock Amgen Inc. (AMGN) Worth Betting on Now?
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Here's Why Amgen (AMGN) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Amgen: The Biotech That Knows How To Make Money
Amgen's strategic growth through M&A and R&D investments has led to a diversified portfolio, with significant contributions from rare disease treatments and biosimilars. Financially robust, Amgen achieved record revenues of $33.4 billion in 2024, with strong EBITDA growth and high free cash flow, despite increased debt from acquisitions. The company's balanced business model and innovative pipeline, including promising drugs in oncology and cardiometabolic diseases, support a "Buy" rating with a 16.44% growth potential.
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
AMGN's Uplizna Gets FDA Nod for 2nd Rare Autoimmune Disease Indication
The FDA approves Amgen's Uplizna as the first and only drug for the treatment of immunoglobulin G4-related disease.
Amgen (AMGN) Rises As Market Takes a Dip: Key Facts
Amgen (AMGN) concluded the recent trading session at $310.09, signifying a +1.44% move from its prior day's close.
Amgen (AMGN) Surpasses Market Returns: Some Facts Worth Knowing
Amgen (AMGN) concluded the recent trading session at $311.55, signifying a +1.5% move from its prior day's close.
Amgen: Excellent Buy And Hold For A Volatile Market
Amgen is a robust long-term investment due to its strong profitability, competitive moat, and promising pipeline, including an anti-obesity drug. Despite modest short-term growth guidance, AMGN's Horizon Therapeutics acquisition and innovation pipeline offer significant long-term potential. AMGN's 3.1% dividend yield, prudent debt management, and reasonable valuation make it an attractive 'buy and hold' stock.
